Exact Sciences Corp. (EXAS) News

Exact Sciences Corp. (EXAS): $63.03

-0.41 (-0.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter EXAS News Items

EXAS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EXAS News Highlights

  • For EXAS, its 30 day story count is now at 22.
  • Over the past 22 days, the trend for EXAS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • AMP, AGE and DX are the most mentioned tickers in articles about EXAS.

Latest EXAS News From Around the Web

Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

EXAS Stock Is a Hidden Gem in the Healthcare Sector for Bold Investors

Patient investors who have room for an intriguing medical-niche investment in their portfolio should take a closer look at EXAS stock.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | March 16, 2023

If You Invested $10,000 in Exact Sciences in 2018, This Is How Much You Would Have Today

Exact Sciences (NASDAQ: EXAS) is a cancer diagnostics company with promising long-term potential. Its Cologuard non-invasive test can detect colorectal cancer and help save lives. Below, I'll look at what a $10,000 investment in Exact Sciences made in 2018 would be worth now, and whether the healthcare stock is a good buy today.

Yahoo | March 16, 2023

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Josh Enomoto on InvestorPlace | March 15, 2023

Exact Sciences (EXAS) Stock Moves -0.16%: What You Should Know

In the latest trading session, Exact Sciences (EXAS) closed at $64.36, marking a -0.16% move from the previous day.

Yahoo | March 15, 2023

7 Growth Stocks Sitting in a Sweet Spot

For instance, these seven growth stocks.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | March 14, 2023

Exact Sciences (EXAS) Gains But Lags Market: What You Should Know

In the latest trading session, Exact Sciences (EXAS) closed at $64.46, marking a +1.45% move from the previous day.

Yahoo | March 14, 2023

Cathie Wood Watch: Ark Buys Block, Tesla

Wood's flagship Ark Innovation ETF has lost 28% during the last year, but has bounced back 21% so far this year.

Yahoo | March 14, 2023

A Nasdaq Bull Market Is Coming: 2 Revolutionary Stocks to Buy and Hold

Last year, the Nasdaq Composite fell into a bear market and lagged behind the other two major U.S. market indexes. Let's consider two revolutionary companies to invest in before that happens: Moderna (NASDAQ: MRNA) and Exact Sciences (NASDAQ: EXAS). Moderna became widely known during the pandemic for being one of the leaders in the coronavirus vaccine market.

Yahoo | March 12, 2023

Cathie Wood Watch: Another Day, Another Coinbase Buy

Wood's flagship Ark Innovation ETF fell 42% during the past year, but has bounced back 15% so far this year.

Yahoo | March 10, 2023

Cathie Wood Watch: Ark Dives Back in to Tesla Shares

Wood's flagship Ark Innovation ETF has dropped 36% over the past year but has rebounded 26% so far this year.

Yahoo | March 9, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7868 seconds.